← All trials
NCT06747845
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 6, 2025
- Primary completion
- Jun 30, 2028
- Completion date
- Jan 30, 2029
- First posted
- Dec 24, 2024
- Last posted
- Dec 24, 2024
- Enrollment
- 68
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of PennsylvaniaLead sponsor
- Bristol-Myers SquibbCollaborator
- GlaxoSmithKlineCollaborator
- Lustgarten FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.